| Fate Therapeutics, Inc. | Barbara Hickingbottom | A Phase 1 Study of FT819 in Participants with Moderate to Severe Active Systemic Lupus Erythematosus |
$7,934,448 |
| University of California, San Francisco | Dr. Hideho Okada | Phase 1 Study of Autologous E-SYNC T Cells in Adult Participants with EGFRvIII+ Glioblastoma |
$10,927,618 |
| ImmPACT-Bio, Inc. | DR Jonathan Benjamin | A phase 1/2 study to evaluate a bispecific CD19/CD20-directed CAR T cell, in refractory lupus nephritis and systemic lupus erythematosus |
$8,000,000 |
| Aspen Neuroscience | Dr. Edward Wirth III | Phase 1/2a Dose Escalation Study of ANPD001 in Sporadic Parkinson Disease |
$8,000,000 |
| Alto Neuroscience | Amit Etkin | A Phase 2b Study of the Efficacy of a Novel Pro-Neurogenesis/Pro-Plasticity Drug for Bipolar Depression Using a Precision Psychiatry Approach |
$15,000,000 |
| University of California, Davis | Dr. Diana L. Farmer | The CuRe Trial: Cellular Therapy for In Utero Repair of Myelomeningocele |
$8,996,477 |
| Stanford University | Dr. Reena Parada Thomas | Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme |
$11,999,991 |
| City of Hope, Beckman Research Institute | Elizabeth Budde | Phase I Study of Chimeric Antigen Receptor Engineered T Cells targeting CD33 for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia |
$11,983,547 |
| Stanford University | Anusha Kalbasi | Stem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors |
$10,211,085 |
| University of California, San Diego | Prof. Olivia Kim-McManus | Personalized antisense oligonucleotide therapy for rare pediatric genetic disease: SCN2A |
$960,713 |
| Regenerative Patch Technologies LLC | Dr Jane S Lebkowski | A Phase 2b, Randomized, Assessor-Masked Clinical Trial to Assess the Safety and Efficacy of the CPCB-RPE1 Implant in Subjects with Geographic Atrophy |
$12,373,748 |
| City of Hope, Beckman Research Institute | Dr. Angelo Manuel Almeida Cardoso Ph.D., MD | Evaluation of Safety and Feasibility of Cytomegalovirus-Specific, Anti-HIV Chimeric Antigen Receptor (CMV/HIV-CAR) T Cells in People with HIV |
$11,299,976 |
| Combangio, Inc. | R. Kim Brazzell | Phase 2b Clinical Study of KPI-012 Topical Ophthalmic Human Mesenchymal Stem Cell Secretome for the Treatment of Persistent Corneal Epithelial Defect |
$15,000,000 |
| Immusoft Corporation | Dr Robert Hayes | A Phase I Open Label Study to Evaluate the Safety and Tolerability of ISP-001 in Patients with Mucopolysaccharidosis Type 1 |
$8,000,000 |
| Eureka Therapeutics, Inc. | Pei Wang | Autologous ARTEMIS® T Cells to Treat Refractory/Relapsed Pediatric Liver Cancer |
$10,600,072 |
| Stanford University | Dr. Matthew H Porteus | Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients |
$10,642,420 |
| Angiocrine Bioscience, Inc. | Dr. Paul Finnegan | AB-205-301 Phase 3 Trial and Related Activities to Support Clinical Development of AB-205 |
$10,930,014 |
| Genascence Corporation | Dr. Thomas W Chalberg Jr. | A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose-Ranging Study of GNSC-001 Evaluating Safety, Pharmacodynamics, and Biomarkers in Knee OA |
$11,637,194 |
| Tachyon Therapeutics, Inc | Ivan King | TACH101: A Potent, First-In-Class KDM4 Inhibitor for Advanced Cancers |
$6,862,609 |
| City of Hope, Beckman Research Institute | Ryotaro Nakamura | Treatment of Severe Aplastic Anemia by induction of mixed chimerism using CD4+ T cell depleted haploidentical donor stem cell transplant |
$9,054,216 |
| Stanford University | Alice Bertaina | Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant |
$11,998,188 |
| Neurona Therapeutics | Dr. Cory R Nicholas | Phase 1/2 Study of NRTX-1001 Neural Cell Therapy in Subjects with Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy |
$7,999,999 |
| Excision BioTherapeutics | William Kennedy | Phase 1 Clinical research program for functional cure of HIV with EBT-101, in-vivo gene therapy |
$6,852,486 |
| Wake Forest University Health Sciences | James Yoo | Phase I Treatment of Urethral Strictures in Humans |
$3,841,593 |
| Stanford University | Dr. Rosa Bacchetta | Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome |
$11,999,179 |
| City of Hope, Beckman Research Institute | Dr Jana Portnow | A Phase I Study of Multiple doses of NSC-Based Oncolytic Virotherapy Administered Intracerebrally to Patients with Recurrent High-Grade Gliomas |
$11,999,984 |
| University of California, Davis | Peter C Belafsky | A Double-Blind Randomized Placebo-Controlled Investigation of Autologous Muscle Derived Progenitor Cells for the Treatment of Dysphagia |
$11,015,936 |
| BioEclipse Therapeutics INC. | Dr. Pamela Reilly Contag | PHASE 1, OPEN LABEL, DOSE-ESCALATION STUDY OF CRX100 IN PATIENTS WITH ADVANCED SOLID TUMORS |
$7,999,689 |
| Stanford University | Dr. Joseph C. Wu | A Phase I, Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes in PaTients with ChrOnic Ischemic Left VentRicular Dysfunction (HECTOR) |
$6,987,507 |
| Stanford University | Crystal Mackall | Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma |
$11,998,310 |
| Stanford University | Dr. Matthew H Porteus | Phase 1/1b study of T-allo10 infusion after HLA-partially matched abdepleted-HSCT in children and young adults with hematologic malignancies. |
$10,563,822 |
| Stanford University | Dr. Gary Steinberg | Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects with Chronic Ischemic Subcortical Stroke |
$11,998,988 |
| Cedars-Sinai Medical Center | Clive Svendsen | CNS10-NPC-GDNF delivered into the motor cortex for the treatment of ALS |
$11,990,372 |
| City of Hope, Beckman Research Institute | Dr. Leo D Wang | Phase I Study of IL13Rα2-Targeting CAR T Cells After Lymphodepletion for Children with Refractory or Recurrent Malignant Brain Tumors |
$8,401,309 |
| Immune-Onc Therapeutics | Joseph Paul Woodard | Phase 1 Clinical Development of IO-202, A First-in-Class Antibody Targeting LILRB4, for the Treatment of AML with Monocytic Differentiation and CMML |
$6,000,000 |
| University of California, Davis | Dr. Diana L. Farmer | The CuRe Trial: Cellular Therapy for In Utero Myelomeningocele Repair |
$8,946,474 |
| Rocket Pharmaceuticals, Inc. | Dr. Gayatri Rao | A Phase I Clinical Trial for a Lentiviral Gene Therapy Targeting the TCIRG1 Gene for Infantile Malignant Osteopetrosis (IMO) |
$1,010,000 |
| University of California, San Francisco | Steven G. Deeks | Anti-HIV duoCAR-T cell therapy for HIV infection |
$8,970,732 |
| Brain Neurotherapy Bio | Krystof S. Bankiewicz | A Phase 1b Safety Study for MRI guided delivery of AAV2-GDNF for the treatment of Parkinson’s disease |
$5,510,462 |
| University of California, Los Angeles | Dr. Sophie X Deng | Safety and Feasibility of Cultivated Autologous Limbal Stem Cells for Limbal Stem Cell Deficiency |
$10,301,486 |
| Cedars-Sinai Medical Center | Clive Svendsen | Clinical Study to Assess Safety and Efficacy of Subretinal Injection of Human Neural Progenitor Cells for Treatment of Retinitis Pigmentosa |
$10,444,063 |
| City of Hope, Beckman Research Institute | Dr Saul J Priceman | A Phase I Study of Chimeric Antigen Receptor Engineered Stem/Memory T Cells for the Treatment of HER2-Positive Brain Metastases |
$9,015,149 |
| Rocket Pharmaceuticals, Inc. | Dr. Kinnari Patel | LADICell |
$5,867,085 |
| University of California, San Diego | Dr. Stephanie Cherqui | Phase 1/2 study for autologous human CD34+ hematopoietic stem cells ex vivo transduced with pCCL-CTNS lentiviral vector for treatment of Cystinosis. |
$11,999,944 |
| jCyte, Inc | Henry John Klassen | A Phase 2 Study of the Safety of Repeat Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Adult Subjects with Retinitis Pigmentosa |
$6,608,592 |
| University of California, San Francisco | Peter Stock | Pancreatic Islets and Parathyroid Gland Co-transplantation for Treatment of Diabetes in the Intra-Muscular Site: PARADIGM |
$11,083,012 |
| Jasper Therapeutics, Inc. | Wendy Pang | A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$2,313,398 |
| Stanford University | Dr. Judith A Shizuru | A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$1,113,487 |
| Stanford University | Dr. Everett H. Meyer | Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$11,955,585 |
| University of California, Los Angeles | Theodore Scott Nowicki | Genetic Modification of Stem Cells and T cells to Activate the Immune System to Target Solid Tumors |
$4,230,000 |
| Angiocrine Bioscience, Inc. | Dr. Edward Kavalerchik | AB-205-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-205 |
$6,192,579 |
| Sangamo BioSciences, Inc. | Bettina Cockroft | A Phase 1/2 Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous HSPC Transplant in Transfusion-dependent β-Thalassemia |
$5,150,000 |
| City of Hope, Beckman Research Institute | Dr. De-Fu Zeng | Treatment of sickle cell disease by induction of mixed chimerism and immune tolerance using CD4+ T-depleted haploidentical blood stem cell transplant |
$4,352,180 |
| Stanford University | Dr. David B. Miklos | Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |
| University of California, San Francisco | Mort Cowan | Gene Transfer for Artemis-Deficient Severe Combined Immunodeficiency Using a Lentiviral Vector to Transduce Autologous CD34 Hematopoietic Stem Cells |
$12,000,000 |
| University of California, Los Angeles | Steven M. Dubinett | A phase I trial of intratumoral administration of CCL21-gene modified dendritic cell (DC) combined with intravenous pembrolizumab for advanced NSCLC |
$10,955,315 |
| Medeor Therapeutics, Inc. | Daniel Brennan | Cellular Immunotherapy for Induction of Immune Tolerance in HLA Matched Living Donor Kidney Transplant Recipients |
$11,217,155 |
| Poseida Therapeutics, Inc. | Rajesh Belani MD | Clinical Study of T stem cell memory (Tscm)-based CAR-T cells in Patients with Multiple Myeloma |
$19,813,407 |
| Children’s Hospital of Los Angeles | Michael A. Pulsipher | Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation (ACES) |
$4,825,587 |
| Calibr | Dr. Kristen A Johnson | Evaluation of the Safety and Tolerability of KA34 in a Phase 1, Double-Blind, Dose Escalation Trial in Patients with Knee Osteoarthritis |
$8,447,523 |
| Angiocrine Bioscience, Inc. | Dr. Edward Kavalerchik | AB-110-001 Phase 1b Trial and Related Activities to Support Clinical Development of AB-110 |
$5,000,000 |
| SanBio, Inc. | Dr. Bijan Nejadnik | A Double-Blind, Controlled Ph 2b Study of the Safety and Efficacy of Modified Stem Cells in Patients with Chronic Motor Deficit from Ischemic Stroke |
$18,970,000 |
| City of Hope, Beckman Research Institute | Dr. Christine E. Brown | Phase I Study of Chimeric Antigen Receptor Engineered Central Memory T cells for the Treatment of Malignant Glioma |
$12,753,854 |
| University of California, San Diego | Thomas J Kipps | A Phase 1b/2a Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in B-Cell Cancers |
$18,292,674 |
| Forty Seven Inc. | Mark Chao | Phase 1b Trial of Hu5F9-G4 Monotherapy or Hu5F9-G4 in Combination with Azacitidine in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome |
$0 |
| BrainStorm Cell Therapeutics | Dr. Ralph Kern | A Phase 3, Randomized, Placebo-controlled Multicenter Study to Evaluate Efficacy & Safety of Repeated Administrations of NurOwn® in Patients with ALS |
$15,912,390 |
| Caladrius Biosciences | Dr. William Sietsema | Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus |
$8,175,946 |
| jCyte, Inc | Henry John Klassen | Phase 2b Clinical Study of Safety and Efficacy of Intravitreal Injection of Retinal Progenitor Cells (jCell) for Treatment of Retinitis Pigmentosa |
$8,295,750 |
| Humacyte, Inc. | Jeffrey Lawson | A Phase 3 Study Comparing the Utility of Human Acellular Vessels to Arteriovenous Fistula in Subjects with End-Stage Renal Disease (California Sites) |
$3,525,000 |
| ViaCyte, Inc. | Manasi Jaiman | Clinical trial of directly vascularized islet cell replacement therapy for high-risk type 1 diabetes |
$13,607,002 |
| Forty Seven Inc. | Mark Chao | A Phase 1b/2 Trial of the Anti-CD47 Antibody Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer |
$0 |
| Nohla Therapeutics Inc | Dr. Colleen Delaney | A Phase 2 Open-Label, Multi-Center, Randomized, Controlled, Optimal Dose-Finding Study of DCC-UCB in Adults Receiving High Dose Chemotherapy for AML |
$4,310,000 |
| St. Jude Children’s Research Hospital | Stephen Gottschalk | Lentiviral Gene Therapy for Infants with X-linked Severe Combined Immunodeficiency using Autologous Bone Marrow Stem Cells and Busulfan Conditioning |
$11,924,780 |
| Cedars-Sinai Medical Center | Dr. Michael I Lewis | Pulmonary Arterial Hypertension Treated with Cardiosphere-Derived Allogeneic Stem Cells |
$7,354,772 |
| Stanford University | Dr Robert Lowsky | Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
| University of California, Los Angeles | Dr. Donald B. Kohn | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$5,827,000 |
| Orchard Therapeutics plc | Leslie Meltzer | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$2,638,745 |
| University of California, Los Angeles | Dr. Donald B Kohn | Efficacy and safety of cryopreserved autologous CD34+ HSC transduced with EFS lentiviral vector encoding for human ADA gene in ADA-SCID subjects |
$10,156,925 |
| Cedars-Sinai Medical Center | Professor Clive Niels Svendsen | Human Neural Progenitors Secreting Glial Cell Line-Derived Neurotrophic Factor (CNS10-NPC-GDNF) for the Treatment of Amyotrophic Lateral Sclerosis |
$6,154,067 |
| University of California, San Francisco | Dr. Tippi C. Mackenzie MD | In Utero Hematopoietic Stem Cell Transplantation For The Treatment Of Fetuses With Alpha Thalassemia Major |
$9,350,000 |
| Humacyte, Inc. | Jeffrey Lawson | A Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison with ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) |
$7,625,000 |
| Capricor, Inc | Dr. Linda Marban | Allogeneic Cardiosphere-Derived Cells for Duchenne Muscular Dystrophy Cardiomyopathy |
$3,376,259 |
| University of California, Davis | Dr Mehrdad Abedi | Stem Cell Gene Therapy for HIV Mediated by Lentivector Transduced, Pre-selected CD34+ Cells in AIDS lymphoma patients |
$8,414,265 |
| ImmunoCellular Therapeutics | Anthony J. Gringeri | A Phase III randomized double-blind, controlled study of ICT 107 with maintenance temozolomide (TMZ) in newly diagnosed glioblastoma following resection and concomitant TMZ chemoradiotherapy |
$5,391,016 |
| Caladrius Biosciences | Robert Dillman | Tumor stem cell-targeted immunotherapy for metastatic melanoma –a randomized phase 3 clinical trial. |
$3,000,000 |
| University of California, Los Angeles | Dr. Donald B. Kohn | A Phase I/II, Non Randomized, Multicenter, Open-Label Study of G1XCGD (Lentiviral Vector Transduced CD34+ Cells) in Patients With X-Linked Chronic Granulomatous Disease |
$7,083,364 |
